News & Events

You are here

See Top 10 CRO article here

Asia-Pacific specialist CRO Novotech has been selected as one of the Top 10 CROs globally by leading industry media magazine Pharma Tech Outlook.

10/05/14

Considerations for Asia Pacific clinical trials

As in many other industries, the emerging markets of Asia represent new frontiers for pharmaceutical and biotechnology companies. In recent years the widespread adoption of GCP across the region has meant the industry now is looking to Asia not...

10/03/14

Asian Century and clinical trials: Issues for consideration by biotechnology companies

As with many other industries, there is a prevailing belief that the 21st Century will be the Asian Century when it comes to drug development and the pharmaceutical industry. Already, markets such as China are predicted to overtake the US to...

23/06/13

Australian CRO Novotech announces expanded Asia reach into Hong Kong and Philippines at DIA 2013

Sydney, Australia, 23 June, 2013 – Novotech, Australia’s largest clinical CRO has expanded its Asia reach into Hong Kong and the Philippines, building on its established network which already includes a presence in Singapore, South Korea, Taiwan...

31/05/13

Experienced Australian CRO attains Medidata accreditation to offer enhanced clinical trial services

Media contact:
Susan Fitzpatrick-Napier
DMG
Australia: +61 2 8006 0424
USA: +1650 7985238
EMAIL: susan@dmgpr.com

NOVOTECH...

06/05/13

NOVOTECH CRO ATTRACTS INVESTMENT FOR ASIA CLINICAL TRIAL EXPANSION

Media contact:
Susan Fitzpatrick-Napier
Digital Mantra Group (DMG)
Australia: +61 2 8006 0424
USA: +1650 7985238
EMAIL:...

04/02/13

Alchemia Recruits Full Patient Quota to Pivotal Phase III HAIrinotecan Trial in Metastatic Colorectal Cancer

Brisbane-based drug discovery and development company Alchemia Limited (ASX: ACL) has recruited the 390th patient to its pivotal Phase III clinical trial
of the Company’s lead cancer drug, HA-Irinotecan, as per its study protocol.

07/12/11

The Road Less Travelled – Navigation through the do’s and don’ts of running Oncology studies in Asia Pacific

Clinical trials in the Asia Pacific are increasing exponentially. Numerous sponsors and CROs have accessed this region in recent years to take advantage of high performing, cost effective sites. 

 

Listen to the...

05/07/11

Novotech in new research collaboration: Biotechnology News

LEADING Australian contract clinical research company Novotech, Marine Biotechnology Australia and the University of Sydney are taking part in a new herpes research collaboration backed by the Academic Research Council (ARC).

05/07/11

TheraVida Initiates Phase 2 Trial of THVD-201 for Overactive Bladder and Urinary Incontinence: selects Novotech

 

TheraVida Initiates Phase 2 Trial of THVD-201 for Overactive Bladder and Urinary Incontinence

Multi-national Study to be Conducted by...

15/06/11

Herpes Zoster Novel Treatment Hope From Tasmanian Abalone Gets $1.2 Million Boost

Sydney, Australia, 23 May 2011 – Leading Australian contract clinical research company Novotech, Marine Biotechnology Australia Pty Ltd [MBA] and the University of Sydney today announced a new Herpes research collaboration backed by the Academic...

Pages